<!DOCTYPE html SYSTEM "about:legacy-compat">
<html lang="en-US" class="no-js">
  <head>
    <meta charset="utf-8"/>
    <title>Chapter 05 Maryland Cancer Fund | Library of Maryland Regulations</title>
    <link rel="shortcut icon" href="/us/md/exec/_document/v2/images/favicons/favicon.ico"/>
    <!--Meta-->
    <meta http-equiv="X-UA-Compatible" content="IE=EDGE"/>
    <meta name="viewport" content="width=device-width, initial-scale=1"/>
    <meta name="format-detection" content="telephone=no"/>
    <meta name="HandheldFriendly" content="true"/>
    <meta itemprop="full-html" content="/us/md/exec/comar/10.14.05/index.full.html" data-document="href"/>
    <meta itemprop="toc-json" content="/us/md/exec/comar/10.14.05/index.json" data-document="href"/>
    <meta itemprop="parent-doc-url" content="/us/md/exec/comar" data-document="href"/>
    <meta itemprop="order" content="|10|14|05|"/>
    <meta itemprop="doc-type" content="container" data-document=""/>
    <meta itemprop="doc-num" content="05"/>
    <meta itemprop="ref-doc" content="Code of Maryland Regulations" data-document=""/>
    <meta itemprop="ref-path" content="10|14|05" data-document=""/>
    <!--OpenGraph-->
    <meta property="og:url" content="http://regs.maryland.gov//us/md/exec/comar/10.14.05"/>
    <meta property="og:type" content="article"/>
    <meta property="og:title" content="Chapter 05 Maryland Cancer Fund | Library of Maryland Regulations"/>
    <meta property="og:image" content="http://regs.maryland.gov//us/md/exec/_document/v2/images/og/og_image.png"/>
    <!--Progressive Web App-->
    <link rel="manifest" href="/manifest.json"/>
    <meta name="apple-mobile-web-app-capable" content="yes"/>
    <meta name="apple-mobile-web-app-status-bar-style" content="#0078EF"/>
    <meta name="apple-mobile-web-app-title" content="Library of Maryland Regulations"/>
    <meta name="theme-color" content="#0078EF"/>
    <meta name="apple-mobile-web-app-capable" content="yes"/>
    <meta name="mobile-web-app-capable" content="yes"/>
    <!--PWA icons-->
    <link rel="apple-touch-icon" sizes="180x180" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="60x60" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-60x60-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="76x76" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-76x76-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="152x152" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-152x152-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="180x180" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-180x180-precomposed.png"/>
    <link rel="mask-icon" href="/us/md/exec/_document/v2/images/favicons/safari-pinned-tab.svg" color="#0078EF"/>
    <link rel="icon" type="image/png" sizes="16x16" href="/us/md/exec/_document/v2/images/favicons/favicon-16x16.png"/>
    <link rel="icon" type="image/png" sizes="32x32" href="/us/md/exec/_document/v2/images/favicons/favicon-32x32.png"/>
    <link rel="icon" type="image/png" sizes="48x48" href="/us/md/exec/_document/v2/images/favicons/favicon-48x48.png"/>
    <!--Fonts-->
    <link href="/us/md/exec/_document/v2/biticons/biticons.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/public-sans/public-sans.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/merriweather/merriweather.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/roboto-mono/roboto-mono.css" type="text/css" rel="stylesheet" data-document=""/>
    <!--Document CSS-->
    <link href="/us/md/exec/_document/v2/styles/responsive.min.css" type="text/css" rel="stylesheet" media="screen" data-document=""/>
    <link href="/us/md/exec/_document/v2/styles/main.min.css" type="text/css" rel="stylesheet" media="screen" data-document=""/>
    <link href="/us/md/exec/_document/v2/styles/print.min.css" type="text/css" rel="stylesheet" media="print" data-document=""/>
    <link href="/_reader/styles/main.min.css" type="text/css" rel="stylesheet"/>
    <script src="/_reader/js/main.js" data-document=""> </script>
    <!--Links to resources that need to be prefetched-->
    <link rel="prefetch" href="/us/md/exec/comar/10.14.05/index.full.html" as="fetch"/>
    <link rel="prefetch" href="/index.json" as="fetch"/>
    <link rel="prefetch" href="/us/md/exec/comar/10.14.05/index.json" as="fetch"/>
  </head>
  <body>
    <div role="region" id="announcer" aria-live="polite" class="sr-only" aria-atomic="true" aria-label="Live messages">
      <p id="message"> </p>
    </div>
    <nav class="visually-hidden">
      <a href="#area__content" class="skip-link">Skip to main content</a>
    </nav>
    <div id="grid" class="ns__document__maryland-dsd">
      <header id="section__header" class="ns__document__maryland-dsd">
        <div id="section__header__inner" class="ns__document__maryland-dsd">
          <div id="area__logo" class="ns__document__maryland-dsd">
            <a href="/" class="logo" aria-label="Logo - Return to library home page">
              <img src="/us/md/exec/_document/v2/images/logo/logo.png" srcset="/us/md/exec/_document/v2/images/logo/logo.png 1x, /us/md/exec/_document/v2/images/logo/logo@2x.png 2x, /us/md/exec/_document/v2/images/logo/logo@3x.png 3x" alt="Library of Maryland Regulations logo"/>
            </a>
          </div>
          <div id="area__main_title" class="ns__document__maryland-dsd">
            <div class="h__library-logotype"><span class="line1">Library of</span> <span class="line2">Maryland Regulations</span></div>
          </div>
        </div>
      </header>
      <div id="section__content" class="ns__document__maryland-dsd">
        <div id="section__content__inner" class="ns__document__maryland-dsd">
          <section id="area__breadcrumbs" class="ns__document__maryland-dsd" role="region" aria-label="Breadcrumbs">
            <input type="checkbox" id="menu-trigger" class="menu-trigger" aria-label="Mobile menu toggler"/>
            <label for="menu-trigger">
              <span class="visually-hidden">Toggle mobile menu</span>
            </label>
            <nav role="navigation" aria-label="Breadcrumb navigation">
              <div class="h__ui">Navigation</div>
              <ul class="ancestors">
                <li data-search-path="library" data-search-heading="All Documents" class="no-indent">
                  <a href="/" title="Library of Maryland Regulations">Library of Maryland Regulations</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations" data-search-heading="" data-search-default="true" class="li__book-open">
                  <a href="/us/md/exec/comar" title="Code of Maryland Regulations">Code of Maryland Regulations</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|10" data-search-heading="">
                  <a href="/us/md/exec/comar/10" title="Title 10 MARYLAND DEPARTMENT OF HEALTH">Title 10 MARYLAND DEPARTMENT OF HEALTH</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|10|14" data-search-heading="">
                  <a href="/us/md/exec/comar/10.14" title="Subtitle 14 CANCER CONTROL">Subtitle 14 CANCER CONTROL</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|10|14|05" data-search-heading="">
                  <span title="Chapter 05 Maryland Cancer Fund">Chapter 05 Maryland Cancer Fund</span>
                </li>
              </ul>
            </nav>
          </section>
          <main id="area__content" class="ns__document__maryland-dsd">
            <div class="h__document-title">Code of Maryland Regulations</div>
            <article class="content" role="document" data-ref-path="10|14|05">
              <div class="tuf-authenticate">
                <h1 class="h__toc" id="/us/md/exec/comar/10.14.05">Chapter 05 Maryland Cancer Fund</h1>
                <section class="line-group annotations">
                  <h2>Administrative History</h2>
                  <p>Effective date:</p>
                  <p>Regulations <a class="internal-link no-wrap" href="/us/md/exec/comar/10.14.05.01" title=".01 Purpose and Scope.">.01</a> — <a class="internal-link no-wrap" href="/us/md/exec/comar/10.14.05.16" title=".16 Payments, Terms and Conditions of Grant Awards, and Terminations.">.16</a> adopted as an emergency provision effective June 1, 2006 (33:15 Md. R. 1274); adopted permanently effective October 9, 2006 (33:20 Md. R. 1616)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.14.05.02#B" title="">Regulation .02B</a> amended as an emergency provision effective June 12, 2008 (35:14 Md. R. 1243); amended permanently effective October 20, 2008 (35:21 Md. R. 1824)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.14.05.02#B" title="">Regulation .02B</a> amended as an emergency provision effective December 22, 2008 (36:2 Md. R. 97); amended permanently effective April 6, 2009 (36:7 Md. R. 524)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.14.05.02#B" title="">Regulation .02B</a> amended effective March 18, 2013 (40:5 Md. R. 411)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.14.05.02#B" title="">Regulation .02B</a> amended as an emergency provision effective January 1, 2014 (41:2 Md. R. 88); amended permanently effective May 12, 2014 (41:9 Md. R. 521)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.14.05.03#A" title="">Regulation .03A</a> amended effective March 18, 2013 (40:5 Md. R. 411)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.14.05.05#C" title="">Regulation .05C</a> amended as an emergency provision effective June 12, 2008 (35:14 Md. R. 1243); amended permanently effective October 20, 2008 (35:21 Md. R. 1824)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.14.05.07" title=".07 Persons Eligible For Grants.">Regulation .07</a> amended as an emergency provision effective June 12, 2008 (35:14 Md. R. 1243); amended permanently effective October 20, 2008 (35:21 Md. R. 1824)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.14.05.08" title=".08 Allowable Uses of the Funds.">Regulation .08</a> amended effective October 4, 2010 (37:20 Md. R. 1393); March 18, 2013 (40:5 Md. R. 411)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.14.05.08" title=".08 Allowable Uses of the Funds.">Regulation .08</a> amended as an emergency provision effective January 1, 2014 (41:2 Md. R. 88); amended permanently effective May 12, 2014 (41:9 Md. R. 521)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.14.05.08#D" title="">Regulation .08D</a>, E amended as an emergency provision effective June 12, 2008 (35:14 Md. R. 1243); amended permanently effective October 20, 2008 (35:21 Md. R. 1824)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.14.05.09" title=".09 Unallowable Uses of Grant Funds.">Regulation .09</a> amended effective March 18, 2013 (40:5 Md. R. 411)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.14.05.10#A" title="">Regulation .10A</a> amended effective March 18, 2013 (40:5 Md. R. 411)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.14.05.11" title=".11 Application Process for Cancer Research Grants.">Regulation .11</a> amended effective March 18, 2013 (40:5 Md. R. 411)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.14.05.12" title=".12 Application Process for Cancer Primary Prevention Grants.">Regulation .12</a> amended effective March 18, 2013 (40:5 Md. R. 411)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.14.05.13" title=".13 Application Process for Cancer Secondary Prevention Grants.">Regulation .13</a> amended effective March 18, 2013 (40:5 Md. R. 411)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.14.05.14" title=".14 Application Process for Cancer Treatment Grants.">Regulation .14</a> amended effective March 18, 2013 (40:5 Md. R. 411)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.14.05.14#C" title="">Regulation .14C</a>, D amended as an emergency provision effective June 12, 2008 (35:14 Md. R. 1243); amended permanently effective October 20, 2008 (35:21 Md. R. 1824)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.14.05.14#D" title="">Regulation .14D</a>, E amended as an emergency provision effective January 1, 2014 (41:2 Md. R. 88); amended permanently effective May 12, 2014 (41:9 Md. R. 521)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.14.05.15" title=".15 Grant Application Review and Approval and Grant Extensions.">Regulation .15</a> amended effective March 18, 2013 (40:5 Md. R. 411)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.14.05.15#B" title="">Regulation .15B</a> amended as an emergency provision effective June 12, 2008 (35:14 Md. R. 1243); amended permanently effective October 20, 2008 (35:21 Md. R. 1824)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.14.05.16#C" title="">Regulation .16C</a> amended effective March 18, 2013 (40:5 Md. R. 411)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.14.05.16#C" title="">Regulation .16C</a> amended as an emergency provision effective January 1, 2014 (41:2 Md. R. 88); amended permanently effective May 12, 2014 (41:9 Md. R. 521)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.14.05.16#D" title="">Regulation .16D</a> amended effective October 4, 2010 (37:20 Md. R. 1393)</p>
                  <h2>Authority</h2>
                  <p>Health-General Article, §20-117; <a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gtg&amp;section=2-112" title="">Tax-General Article, §2-112</a>; Annotated Code of Maryland</p>
                </section>
                <h2 id="/us/md/exec/comar/10.14.05.01" data-order="|10|14|05|.01|" data-ref-path="10|14|05|.01" class="h__section">.01 Purpose and Scope.</h2>
                <p>This chapter:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.01#A">A.</span> Defines the Maryland Cancer Fund;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.01#B">B.</span> Describes how contributions may be made to the Maryland Cancer Fund;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.01#C">C.</span> Sets forth the responsibilities of the Maryland Department of Health and the Comptroller with respect to the Maryland Cancer Fund;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.01#D">D.</span> Identifies eligible applicants; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.01#E">E.</span> Outlines the grant application process for the Maryland Cancer Fund.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.14.05.02" data-order="|10|14|05|.02|" data-ref-path="10|14|05|.02" class="h__section">.02 Definitions.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#A">A.</span> In this chapter, the following terms have the meanings indicated.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B">B.</span> Terms Defined.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(1)">(1)</span> "Annual family income" means the total amount received per year from all sources before taxes are withheld.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(2)">(2)</span> "Applicant" means a person who has applied to receive a grant under the Maryland Cancer Fund.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(3)">(3)</span> "Applied research" means research that is undertaken to determine:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(3)(a)">(a)</span> Possible uses for the findings of basic research; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(3)(b)">(b)</span> New ways of achieving some specific objective.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(4)">(4)</span> "Authorized representative" means an individual or organization that has received permission from an individual diagnosed with cancer to perform certain tasks on the individual's behalf.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(5)">(5)</span> "Basic research" means experimental or theoretical work undertaken to acquire new knowledge or understanding of cancer.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(6)">(6)</span> "Case management" means the coordination of services by a health care professional for an individual for cancer:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(6)(a)">(a)</span> Screening;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(6)(b)">(b)</span> Diagnosis; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(6)(c)">(c)</span> Treatment.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(7)">(7)</span> "Capital expenditures" means money spent to add or expand property, equipment, and assets that will benefit an organization in the long term.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(8)">(8)</span> "Center for Cancer Prevention and Control (CCPC)" means a unit of the Maryland Department of Health within the Prevention and Health Promotion Administration.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(9)">(9)</span> "Clinical research" means research:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(9)(a)">(a)</span> Conducted primarily on patients; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(9)(b)">(b)</span> Designed to answer questions about the etiology, prevention, early detection, diagnosis, or treatment of cancer.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(10)">(10)</span> "Community-based participatory research" means a collaborative, partnership approach to research that equitably involves community members, organizational representatives, and researchers in all aspects of the research process.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(11)">(11)</span> "Comptroller" means the Comptroller of the Treasury.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(12)">(12)</span> "Coinsurance" means the percent of allowable charges for a medical service that an individual with health insurance is responsible for paying.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(13)">(13)</span> "Copayment (copay)" means the set amount of money that an individual with health insurance is responsible for paying each time the individual receives a medical service.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(14)">(14)</span> "County" means a county of this State or Baltimore City.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(15)">(15)</span> "Current Procedure Terminology (CPT)" means the uniform descriptive terms and identifying codes for reporting medical services and procedures performed by physicians.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(16)">(16)</span> "Deductible" means the amount of money that an individual with health insurance is required to pay before the individual's health insurance starts coverage.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(17)">(17)</span> "Department" means the Maryland Department of Health.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(18)">(18)</span> "Diagnosis" means a histopathologic finding of cancer in a:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(18)(a)">(a)</span> Biopsy; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(18)(b)">(b)</span> Surgical specimen.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(19)">(19)</span> Educational Institution.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(19)(a)">(a)</span> "Educational institution" means an organization whose primary mission is to educate individuals.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(19)(b)">(b)</span> "Educational institution" includes:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(19)(b)(i)">(i)</span> Private and public elementary schools;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(19)(b)(ii)">(ii)</span> Middle schools;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(19)(b)(iii)">(iii)</span> High schools;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(19)(b)(iv)">(iv)</span> Colleges;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(19)(b)(v)">(v)</span> Universities;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(19)(b)(vi)">(vi)</span> Graduate schools; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(19)(b)(vii)">(vii)</span> Research institutions.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(20)">(20)</span> "Family" means the unit comprised of all of the following that apply:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(20)(a)">(a)</span> For a financially independent adult 18 years old or older diagnosed with cancer, the adult diagnosed with cancer or the adult diagnosed with cancer and one or more of the following:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(20)(a)(i)">(i)</span> Spouse;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(20)(a)(ii)">(ii)</span> Financially dependent child; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(20)(a)(iii)">(iii)</span> Financially dependent relative; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(20)(b)">(b)</span> For a financially dependent child, the child and one or more of the following:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(20)(b)(i)">(i)</span> Parent, foster parent, or guardian;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(20)(b)(ii)">(ii)</span> Sibling living in the household; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(20)(b)(iii)">(iii)</span> Half brother or half sister living in the household.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(21)">(21)</span> “Federal poverty level” means the poverty guidelines, as amended, which are updated periodically in the Federal Register by the U.S. Department of Health and Human Services and which are incorporated by reference by <a class="internal-link no-wrap" href="/us/md/exec/comar/10.11.03.01" title=".01 Incorporation by Reference.">COMAR 10.11.03.01</a>–1.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(22)">(22)</span> "Fund" means the Maryland Cancer Fund.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(23)">(23)</span> Grant.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(23)(a)">(a)</span> "Grant" means financial assistance from the State to support an applicant's activities related to cancer:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(23)(a)(i)">(i)</span> Research;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(23)(a)(ii)">(ii)</span> Primary prevention;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(23)(a)(iii)">(iii)</span> Secondary prevention; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(23)(a)(iv)">(iv)</span> Treatment.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(23)(b)">(b)</span> "Grant" does not mean a contract.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(24)">(24)</span> "Governmental entity" means a federal, State, or local governmental organization.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(25)">(25)</span> "Health Services Cost Review Commission (HSCRC)" means the independent organization within the Department that is responsible for reviewing and approving rates for hospitals pursuant to Health-General Article, Title 19, Subtitle 2, Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(26)">(26)</span> "Hospital" means an institution that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(26)(a)">(a)</span> Operates within the jurisdiction of Health-General Article, Title 19, Subtitle 3, Annotated Code of Maryland; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(26)(b)">(b)</span> Is licensed pursuant to <a class="internal-link no-wrap" href="/us/md/exec/comar/10.07.01" title="Chapter 01 Acute General Hospitals and Special Hospitals">COMAR 10.07.01</a> or other applicable standards established by the jurisdiction in which the service is provided.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(27)">(27)</span> "Laboratory" means a licensed or certified facility operated for the examination of material derived from the human body for the purpose of obtaining information for the diagnosis, treatment, and management of a disease.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(28)">(28)</span> "Local health department" means a governmental entity in a county in Maryland that provides public health services.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(29)">(29)</span> "Major medical equipment" means equipment that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(29)(a)">(a)</span> Costs in excess of $500; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(29)(b)">(b)</span> Is used for the provision of medical or health services.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(30)">(30)</span> "Maryland Comprehensive Cancer Control Plan" means the most recent edition of the cancer plan developed by the Department.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(31)">(31)</span> "Maryland Health Insurance Plan (MHIP)" means a State-administered program that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(31)(a)">(a)</span> Is operated by a unit within the Maryland Insurance Administration under <a class="internal-link " href="https://mgaleg.maryland.gov/2023RS/Statute_Web/gin/gin.pdf" title="">Insurance Article, Title 14, Subtitle 5, Annotated Code of Maryland</a>; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(31)(b)">(b)</span> Provides health insurance coverage to medically uninsurable Maryland residents.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(32)">(32)</span> "Medical Assistance" means the program administered by the State under Title XIX of the Social Security Act, 42 U.S.C. §§1396 — 1396v, which provides comprehensive medical and other health-related care for eligible categorically and medically needy persons.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(33)">(33)</span> "Medicare" means the medical insurance program administered by the federal government under Title XVIII of the Social Security Act, 42 U.S.C. §§1395 — 1395hhh.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(34)">(34)</span> “Patient contribution amount” means the amount of money required by an individual’s health insurance policy to be paid by the individual for a given medical procedure or service received, excluding the deductible.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(35)">(35)</span> "Physician" means an individual who is licensed to practice medicine in the jurisdiction in which the service is provided.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(36)">(36)</span> "Premium" means the amount of money than an individual pays in regular installments to a health insurer for a health insurance policy.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(37)">(37)</span> Primary Prevention.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(37)(a)">(a)</span> "Primary prevention" means activities to prevent or reduce the development of cancer.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(37)(b)">(b)</span> "Primary prevention" includes interventions such as:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(37)(b)(i)">(i)</span> Tobacco use prevention and cessation;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(37)(b)(ii)">(ii)</span> Protection from ultraviolet light;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(37)(b)(iii)">(iii)</span> Proper nutrition and physical activity; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(37)(b)(iv)">(iv)</span> Reduction of exposure to environmental and occupational carcinogens.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(38)">(38)</span> Research.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(38)(a)">(a)</span> "Research" means activities to develop or advance the understanding of cancer or the techniques or modalities effective in the prevention, cure, screening, diagnosis, or treatment of cancer.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(38)(b)">(b)</span> "Research" includes basic, clinical, applied, translational, and community-based participatory research.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(39)">(39)</span> "Secondary prevention" means activities to detect and diagnose cancer in its early stages, when the chances of treatment and control are the greatest.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(40)">(40)</span> "Secretary" means the Secretary of Health.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(41)">(41)</span> "Translational research" means using or applying new discoveries to benefit patient care.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(42)">(42)</span> "Treatment" means the medical management and care of a patient that is provided for:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(42)(a)">(a)</span> Obtaining a cancer diagnosis, determining the full extent of the cancer spread, or treating the cancer, including:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(42)(a)(i)">(i)</span> Surgery;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(42)(a)(ii)">(ii)</span> Chemotherapy;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(42)(a)(iii)">(iii)</span> Radiation therapy;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(42)(a)(iv)">(iv)</span> Hormonal therapy;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(42)(a)(v)">(v)</span> Biopsy;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(42)(a)(vi)">(vi)</span> Imaging procedures;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(42)(a)(vii)">(vii)</span> Laboratory testing;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(42)(a)(viii)">(viii)</span> Home health services; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(42)(a)(ix)">(ix)</span> Medical supplies or medical equipment;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(42)(b)">(b)</span> Treating medical complications resulting from cancer screening or treatment;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(42)(c)">(c)</span> Treating other co-morbid conditions in order to treat cancer; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(42)(d)">(d)</span> Providing palliative or end-of-life care.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(43)">(43)</span> "Uninsured" means that an individual:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(43)(a)">(a)</span> Does not have any health insurance; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.02#B(43)(b)">(b)</span> Has health insurance that does not cover the cancer prevention, screening, diagnosis, or treatment services provided under the Fund.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.14.05.03" data-order="|10|14|05|.03|" data-ref-path="10|14|05|.03" class="h__section">.03 Maryland Cancer Fund.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.03#A">A.</span> The Maryland Cancer Fund is a nonlapsing, special fund created by Health-General Article, §20-117, Annotated Code of Maryland, for cancer research, prevention, and treatment, which is generated from:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.03#A(1)">(1)</span> Contributions from the income tax checkoff system under <a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gtg&amp;section=2-112" title="">Tax-General Article, §2-112, Annotated Code of Maryland</a>; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.03#A(2)">(2)</span> Any other donations to the Fund.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.03#B">B.</span> The Department may only expend funds:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.03#B(1)">(1)</span> In accordance with an appropriation approved by the General Assembly in the annual State budget; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.03#B(2)">(2)</span> Through an approved budget amendment under State Finance and Procurement Article, §§<a class="internal-link no-wrap" href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gsf&amp;section=7-209" title="">7-209</a> and <a class="internal-link no-wrap" href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gsf&amp;section=7-210" title="">7-210</a>, Annotated Code of Maryland.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.03#C">C.</span> The Department may only make grant awards under the Fund for cancer:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.03#C(1)">(1)</span> Research;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.03#C(2)">(2)</span> Primary prevention;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.03#C(3)">(3)</span> Secondary prevention; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.03#C(4)">(4)</span> Treatment.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.03#D">D.</span> Any unspent portions of the Fund shall remain in the Fund and may not revert to the General Fund of the State.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.03#E">E.</span> Money expended from the Fund is supplemental to, and is not intended to take the place of, funding that would otherwise be appropriated to the Department for cancer:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.03#E(1)">(1)</span> Research;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.03#E(2)">(2)</span> Primary prevention;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.03#E(3)">(3)</span> Secondary prevention; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.03#E(4)">(4)</span> Treatment.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.14.05.04" data-order="|10|14|05|.04|" data-ref-path="10|14|05|.04" class="h__section">.04 Contributions to the Maryland Cancer Fund.</h2>
                <p>An individual or each spouse in the case of a joint income tax return may contribute an amount to the Fund by:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.04#A">A.</span> Deducting the amount of the contribution from any refund due under a tax return; or</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.04#B">B.</span> Adding the amount of the contribution to the income tax to be paid with a tax return.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.14.05.05" data-order="|10|14|05|.05|" data-ref-path="10|14|05|.05" class="h__section">.05 Responsibilities of the Department.</h2>
                <p>The Department:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.05#A">A.</span> Shall administer the Fund;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.05#B">B.</span> May not spend more than 5 percent of the proceeds received from the Comptroller for the Fund to promote further donations to the Fund; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.05#C">C.</span> Shall provide a grant in each fiscal year to persons to conduct one or more of the following cancer-related activities:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.05#C(1)">(1)</span> Research;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.05#C(2)">(2)</span> Primary prevention;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.05#C(3)">(3)</span> Secondary prevention; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.05#C(4)">(4)</span> Treatment.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.14.05.06" data-order="|10|14|05|.06|" data-ref-path="10|14|05|.06" class="h__section">.06 Responsibilities of the Comptroller.</h2>
                <p>The Comptroller shall:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.06#A">A.</span> Include in the individual income tax return form:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.06#A(1)">(1)</span> A checkoff designated as the Maryland Cancer Fund contribution; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.06#A(2)">(2)</span> A description that the Fund may only be used for cancer:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.06#A(2)(a)">(a)</span> Research;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.06#A(2)(b)">(b)</span> Primary prevention;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.06#A(2)(c)">(c)</span> Secondary prevention; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.06#A(2)(d)">(d)</span> Treatment;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.06#B">B.</span> Collect the checkoff contributions and other donations and account to the Treasurer for the money collected;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.06#C">C.</span> Distribute the amount necessary to administer the checkoff system to an administrative cost account;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.06#D">D.</span> After the distribution under <a class="internal-link " href="/us/md/exec/comar/10.14.05.06#C" title="">§C of this regulation</a>, distribute the remainder of the money to the Fund; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.06#E">E.</span> Notify the Department annually of:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.06#E(1)">(1)</span> The gross amount of donations to the Fund through the income tax checkoff system;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.06#E(2)">(2)</span> The gross amount of other donations to the Fund; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.06#E(3)">(3)</span> The costs of administration of the income tax checkoff system by the Comptroller.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.14.05.07" data-order="|10|14|05|.07|" data-ref-path="10|14|05|.07" class="h__section">.07 Persons Eligible For Grants.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.07#A">A.</span> Subject to any limitations imposed under <a class="internal-link " href="/us/md/exec/comar/10.14.05.07#B" title="">§B of this regulation</a>, the following persons are eligible to receive a grant from the Department for cancer research, primary prevention, secondary prevention, or treatment:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.07#A(1)">(1)</span> Physicians;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.07#A(2)">(2)</span> Hospitals;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.07#A(3)">(3)</span> Laboratories;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.07#A(4)">(4)</span> Educational institutions;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.07#A(5)">(5)</span> Local health departments;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.07#A(6)">(6)</span> Governmental entities; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.07#A(7)">(7)</span> Another person or organization with expertise in cancer research, primary prevention, secondary prevention, or treatment.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.07#B">B.</span> The Department may limit the persons eligible to receive a grant in <a class="internal-link " href="/us/md/exec/comar/10.14.05.07#A" title="">§A of this regulation</a> based on:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.07#B(1)">(1)</span> Availability of funds; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.07#B(2)">(2)</span> The Department's ability to account for and monitor the grant funding.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.07#C">C.</span> In order to be eligible to receive a grant, an applicant:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.07#C(1)">(1)</span> May be a nonprofit or for-profit entity;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.07#C(2)">(2)</span> Shall have an office located in Maryland; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.07#C(3)">(3)</span> May only propose work that will serve or benefit one or more Maryland residents.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.14.05.08" data-order="|10|14|05|.08|" data-ref-path="10|14|05|.08" class="h__section">.08 Allowable Uses of the Funds.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.08#A">A.</span> A grantee that is funded to conduct cancer research by the Fund may use the grant funds:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.08#A(1)">(1)</span> For basic, clinical, translational, applied, or community-based participatory research;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.08#A(2)">(2)</span> To support:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.08#A(2)(a)">(a)</span> The individuals engaged in the research; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.08#A(2)(b)">(b)</span> The individual's support staff; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.08#A(3)">(3)</span> To purchase office supplies.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.08#B">B.</span> A grantee that is funded to conduct cancer primary prevention or secondary prevention by the Fund may use the grant funds for:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.08#B(1)">(1)</span> Education;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.08#B(2)">(2)</span> Outreach;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.08#B(3)">(3)</span> Policy changes;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.08#B(4)">(4)</span> Provider interventions;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.08#B(5)">(5)</span> Clinical services;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.08#B(6)">(6)</span> Case management;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.08#B(7)">(7)</span> Quality assurance;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.08#B(8)">(8)</span> Data collection; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.08#B(9)">(9)</span> Partnership development.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.08#C">C.</span> If a grantee is funded to conduct cancer secondary prevention services, the Fund shall provide to the grantee reimbursement for a clinical service at a rate not higher than the rate that:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.08#C(1)">(1)</span> Medicare pays for the clinical service in the region; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.08#C(2)">(2)</span> The HSCRC has approved for the clinical service, if the clinical service is provided by a HSCRC-regulated facility.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.08#D">D.</span> If a grantee is funded to conduct cancer secondary prevention or treatment, the grantee shall only provide clinical services to individuals who:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.08#D(1)">(1)</span> Are Maryland residents; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.08#D(2)">(2)</span> Have an annual family income that is not more than 250 percent of the federal poverty guidelines.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.08#E">E.</span> If a grantee is funded to conduct cancer treatment, a grantee may use the grant funds:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.08#E(1)">(1)</span> For grants awarded before January 1, 2014 to provide MHIP reimbursement, to pay up to a maximum of $15,000 for direct costs per individual per year for the premium, deductible, coinsurance, and copay of the MHIP costs and for services not covered under MHIP; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.08#E(2)">(2)</span> To pay up to a specified amount, as determined by the Department, for direct costs per individual per year for the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.08#E(2)(a)">(a)</span> Deductible and patient contribution amount for the reimbursed medical procedure or service for insured individuals; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.08#E(2)(b)">(b)</span> Medical procedure or service not covered under their health insurance policy for individuals who meet the eligibility criteria of <a class="internal-link " href="/us/md/exec/comar/10.14.05.08#D" title="">§D of this regulation</a>; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.08#E(3)">(3)</span> To pay up to a maximum of $20,000 for direct costs per individual per year for the cancer treatment costs under the individual’s treatment plan:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.08#E(3)(a)">(a)</span> Who meet the eligibility criteria in <a class="internal-link " href="/us/md/exec/comar/10.14.05.08#D" title="">§D of this regulation</a>; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.08#E(3)(b)">(b)</span> At a rate not to exceed the rate that Medical Assistance pays for clinical services or the rate that the HSCRC has approved for the clinical services, if treatment is provided by a HSCRC-regulated facility.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.08#F">F.</span> If a grantee is funded to pay for cancer treatment:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.08#F(1)">(1)</span> Under <a class="internal-link " href="/us/md/exec/comar/10.14.05.08#E(1)" title="">§E(1) of this regulation</a>, the grantee shall only pay or direct the Department to pay MHIP the following for services directly related to the treatment of cancer for the individual diagnosed with cancer:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.08#F(1)(a)">(a)</span> Premiums;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.08#F(1)(b)">(b)</span> Deductibles;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.08#F(1)(c)">(c)</span> Coinsurance; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.08#F(1)(d)">(d)</span> Copays;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.08#F(2)">(2)</span> Under <a class="internal-link " href="/us/md/exec/comar/10.14.05.08#E(2)" title="">§E(2) of this regulation</a>, the grantee shall only pay or direct the Department to pay the deductible and patient contribution amount for the reimbursed medical procedure or service that the individual is required to pay for the services directly related to the diagnosis and treatment of cancer; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.08#F(3)">(3)</span> May not pay any amount for the individual’s spouse, children, or other family members’ health insurance costs.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.08#G">G.</span> For the purpose of §F(1) and (2) of this regulation, the Department shall pay the health insurance costs out of the funds that are set aside for the grantee.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.08#H">H.</span> In addition to the direct costs allowed under <a class="internal-link " href="/us/md/exec/comar/10.14.05.08#E" title="">§E of this regulation</a>, the Fund shall also pay a maximum of 7 percent of the indirect costs to local health department grantees or non-local health department grantees.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.14.05.09" data-order="|10|14|05|.09|" data-ref-path="10|14|05|.09" class="h__section">.09 Unallowable Uses of Grant Funds.</h2>
                <p>A grantee may not use grant funds from the Fund to pay for:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.09#A">A.</span> Major medical equipment purchases;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.09#B">B.</span> Renovations;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.09#C">C.</span> Capital expenditures; or</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.09#D">D.</span> Cancer prevention or cancer treatment that would be provided by an individual's existing health insurance, including:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.09#D(1)">(1)</span> Medical Assistance;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.09#D(2)">(2)</span> Medicare; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.09#D(3)">(3)</span> Private health insurance.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.14.05.10" data-order="|10|14|05|.10|" data-ref-path="10|14|05|.10" class="h__section">.10 Grant Application.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.10#A">A.</span> A person may obtain an application packet from the CCPC for a cancer:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.10#A(1)">(1)</span> Research grant;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.10#A(2)">(2)</span> Primary prevention grant;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.10#A(3)">(3)</span> Secondary prevention grant; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.10#A(4)">(4)</span> Treatment grant.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.10#B">B.</span> An applicant may:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.10#B(1)">(1)</span> Apply for one or more grants in any fiscal year; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.10#B(2)">(2)</span> Combine multiple requests for cancer research, primary prevention, or secondary prevention grants within a single application, provided that the information required for separate grant applications is included in the combined application.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.14.05.11" data-order="|10|14|05|.11|" data-ref-path="10|14|05|.11" class="h__section">.11 Application Process for Cancer Research Grants.</h2>
                <p>An applicant for a cancer research grant shall:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.11#A">A.</span> Submit a completed application to the CCPC by the due date listed in the application packet; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.11#B">B.</span> Include in the application packet the following information as specified in the Department’s application packet:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.11#B(1)">(1)</span> An executive summary stating:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.11#B(1)(a)">(a)</span> How the grant funds will be used;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.11#B(1)(b)">(b)</span> What institutions and other persons will be involved in the research;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.11#B(1)(c)">(c)</span> Whether basic, clinical, applied, translational, or community-based research is being proposed;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.11#B(1)(d)">(d)</span> Whether the proposed research is included in a recommendation of the Maryland Comprehensive Cancer Control Plan; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.11#B(1)(e)">(e)</span> How the grant money is expected to further the knowledge of cancer;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.11#B(2)">(2)</span> A statement of the need for the cancer research, including:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.11#B(2)(a)">(a)</span> Previous literature in the area; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.11#B(2)(b)">(b)</span> Any work that the applicant has done in the research area;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.11#B(3)">(3)</span> A proposed cancer research plan describing:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.11#B(3)(a)">(a)</span> How the grant funds will be used;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.11#B(3)(b)">(b)</span> Who will be involved in the research;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.11#B(3)(c)">(c)</span> What the anticipated results of the research with the grant funds will be; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.11#B(3)(d)">(d)</span> What goals, objectives, and activities will be pursued with the grant funds;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.11#B(4)">(4)</span> A brief professional resume or curriculum vitae of:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.11#B(4)(a)">(a)</span> The principal investigator; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.11#B(4)(b)">(b)</span> Other key staff;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.11#B(5)">(5)</span> A description of how the proposed research will help to eliminate disparities between racial and ethnic minorities and the white population;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.11#B(6)">(6)</span> A list of the institutional review boards to which the research will be submitted for review and approval before the research is initiated, including the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.11#B(6)(a)">(a)</span> Department's Institutional Review Board; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.11#B(6)(b)">(b)</span> Applicant's relevant institutional review board;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.11#B(7)">(7)</span> A timeline showing the expected start date and completion date for each activity to be conducted under the grant, including application to and approval from the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.11#B(7)(a)">(a)</span> Department's Institutional Review Board; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.11#B(7)(b)">(b)</span> Applicant's relevant institutional review board;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.11#B(8)">(8)</span> An organizational chart showing where the work under the research grant is located within the applicant's organization;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.11#B(9)">(9)</span> A statement that the grant funds will not be used to supplant any existing funding for this cancer research and, if an applicant receives funding for a similar cancer research activity, a listing of the funding:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.11#B(9)(a)">(a)</span> Source;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.11#B(9)(b)">(b)</span> Amount; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.11#B(9)(c)">(c)</span> Period for the activity;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.11#B(10)">(10)</span> A line item budget for the cancer research grant; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.11#B(11)">(11)</span> A written budget justification for each line item request.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.14.05.12" data-order="|10|14|05|.12|" data-ref-path="10|14|05|.12" class="h__section">.12 Application Process for Cancer Primary Prevention Grants.</h2>
                <p>An applicant for a cancer primary prevention grant shall:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.12#A">A.</span> Submit a completed application to the CCPC by the due date listed in the application packet; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.12#B">B.</span> Include in the application packet the following information, as specified in the Department's application packet:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.12#B(1)">(1)</span> An executive summary describing:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.12#B(1)(a)">(a)</span> How the grant funds will be used;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.12#B(1)(b)">(b)</span> What persons will be involved in the grant activities;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.12#B(1)(c)">(c)</span> What cancer primary prevention activities will be conducted;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.12#B(1)(d)">(d)</span> Whether the primary prevention activities are included in a recommendation in the Maryland Comprehensive Cancer Control Plan;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.12#B(1)(e)">(e)</span> What population groups will be served and in what jurisdiction groups will be served;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.12#B(1)(f)">(f)</span> What types of services will be offered, including education and policy initiatives:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.12#B(1)(g)">(g)</span> What the eligibility for services will be; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.12#B(1)(h)">(h)</span> What outcome is expected as a result of the funding;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.12#B(2)">(2)</span> A statement of the need for the cancer primary prevention intervention;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.12#B(3)">(3)</span> A description of previous literature in the area documenting the effectiveness of the cancer primary prevention intervention;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.12#B(4)">(4)</span> A proposed cancer primary prevention plan describing the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.12#B(4)(a)">(a)</span> Estimated number of persons to be served;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.12#B(4)(b)">(b)</span> Goals, objectives, and activities to be conducted with the grant funds;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.12#B(4)(c)">(c)</span> Evaluation measures for each activity;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.12#B(4)(d)">(d)</span> How the grant funds will be used;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.12#B(4)(e)">(e)</span> Who will be involved in the plan; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.12#B(4)(f)">(f)</span> What the expected results of the activity with the grant funds are;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.12#B(5)">(5)</span> A description of how the primary prevention plan will address the goal of eliminating disparities between racial and ethnic minorities and the white population;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.12#B(6)">(6)</span> A list of key staff to be involved in the project, including:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.12#B(6)(a)">(a)</span> If existing staff will be used in the project, a description of the experience of the key staff in carrying out similar cancer primary prevention activities; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.12#B(6)(b)">(b)</span> If new staff will be hired for the grant, a job description of the staff that will be responsible for carrying out the project;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.12#B(7)">(7)</span> A description of the previous experience of the applicant's organization in implementing similar cancer primary prevention activities;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.12#B(8)">(8)</span> A timeline showing the expected start date and completion date for each activity to be conducted under the grant;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.12#B(9)">(9)</span> An organizational chart showing:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.12#B(9)(a)">(a)</span> Where the activities under the cancer primary prevention grant falls within the applicant's organizational structure; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.12#B(9)(b)">(b)</span> The relationship of the applicant with other organizations involved in the project;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.12#B(10)">(10)</span> A statement that the grant funds will not be used to supplant any existing funding for this cancer primary prevention activity and, if an applicant receives funding for a similar cancer primary prevention activity a list of the funding:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.12#B(10)(a)">(a)</span> Source;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.12#B(10)(b)">(b)</span> Amount; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.12#B(10)(c)">(c)</span> Period for the activity;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.12#B(11)">(11)</span> A line item budget for the cancer primary prevention grant; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.12#B(12)">(12)</span> A written budget justification for each line item requested.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.14.05.13" data-order="|10|14|05|.13|" data-ref-path="10|14|05|.13" class="h__section">.13 Application Process for Cancer Secondary Prevention Grants.</h2>
                <p>An applicant for a cancer secondary prevention grant shall:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#A">A.</span> Submit a completed application to the CCPC by the due date stated in the application packet; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B">B.</span> Include in the application packet the following information, as specified in the Department's application packet:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(1)">(1)</span> An executive summary describing:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(1)(a)">(a)</span> How the grant funds will be used;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(1)(b)">(b)</span> What persons will be involved in the application;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(1)(c)">(c)</span> What cancer secondary prevention activities will be conducted;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(1)(d)">(d)</span> Whether the proposed activities are included in a recommendation in the Maryland Comprehensive Cancer Control Plan;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(1)(e)">(e)</span> What population groups will be served and in what jurisdiction groups will be served;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(1)(f)">(f)</span> What services will be offered, such as:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(1)(f)(i)">(i)</span> Outreach;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(1)(f)(ii)">(ii)</span> Screening;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(1)(f)(iii)">(iii)</span> Case management;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(1)(f)(iv)">(iv)</span> Quality assurance;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(1)(f)(v)">(v)</span> Data collection; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(1)(f)(vi)">(vi)</span> Partnership building;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(1)(g)">(g)</span> What the eligibility for services will be; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(1)(h)">(h)</span> What outcome is expected as a result of the grant funds;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(2)">(2)</span> A description of previous literature in the area documenting the effectiveness of the cancer secondary prevention activity;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(3)">(3)</span> A description and justification of the need for the cancer secondary prevention activity in the population group to be served;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(4)">(4)</span> A description of the population to be served including, at a minimum, a description of the following for the individuals to be served:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(4)(a)">(a)</span> Age;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(4)(b)">(b)</span> Race;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(4)(c)">(c)</span> Gender;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(4)(d)">(d)</span> Residency;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(4)(e)">(e)</span> Educational level;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(4)(f)">(f)</span> Income level; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(4)(g)">(g)</span> Health insurance requirements of persons to be served;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(5)">(5)</span> A description of the screening guidelines to be used for clinical services and the eligibility guidelines for these services, including age, symptoms, and, if appropriate, risk factors;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(6)">(6)</span> A description of the reimbursement levels to be used for clinical services provided with grant funds;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(7)">(7)</span> A proposed cancer secondary prevention plan describing:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(7)(a)">(a)</span> The estimated number of individuals to be served;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(7)(b)">(b)</span> The goals, objectives, and activities to be conducted with the grant funds;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(7)(c)">(c)</span> Evaluation measures for each activity;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(7)(d)">(d)</span> Who will be involved in the plan; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(7)(e)">(e)</span> What the expected results of the funded activity are;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(8)">(8)</span> A description of how the proposed cancer secondary prevention activities will address the goal of eliminating disparities between racial and ethnic minorities and the white population;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(9)">(9)</span> A list of key staff to be involved in the project, including:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(9)(a)">(a)</span> If existing staff will be used in the project, a description of the experience of the key staff in carrying out similar cancer secondary prevention activities; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(9)(b)">(b)</span> If new staff will be hired for this activity, a job description of the staff responsible for carrying out the project;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(10)">(10)</span> A description of the previous experience of the applicant's organization in implementing similar cancer secondary prevention activities;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(11)">(11)</span> A timeline showing the expected start date and completion date for each activity to be conducted with the grant funds;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(12)">(12)</span> An organizational chart showing:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(12)(a)">(a)</span> Where the cancer secondary prevention grant activities fall within the applicant's organizational structure; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(12)(b)">(b)</span> The relationship of the applicant with other organizations involved in the project;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(13)">(13)</span> A statement that the grant funds will not be used to supplant any existing funding for this cancer secondary prevention activity and, if an applicant receives funding for a similar cancer secondary prevention activity, a list of the funding:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(13)(a)">(a)</span> Source;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(13)(b)">(b)</span> Amount; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(13)(c)">(c)</span> Period for the activity;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(14)">(14)</span> A line item budget for the cancer secondary prevention grant; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.13#B(15)">(15)</span> A written budget justification for each line item requested.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.14.05.14" data-order="|10|14|05|.14|" data-ref-path="10|14|05|.14" class="h__section">.14 Application Process for Cancer Treatment Grants.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#A">A.</span> An applicant for a cancer treatment grant shall submit a completed application to the CCPC.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#B">B.</span> Cancer treatment grants are open and continuous throughout the year to the extent that funding is available.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C">C.</span> An applicant seeking a cancer treatment grant to pay for cancer treatment costs shall include in the Department's application packet:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(1)">(1)</span> A completed cancer treatment grant application for each individual for whom grant funds are being requested, including the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(1)(a)">(a)</span> Name;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(1)(b)">(b)</span> Phone number;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(1)(c)">(c)</span> Mailing address;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(1)(d)">(d)</span> County; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(1)(e)">(e)</span> Signature of the:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(1)(e)(i)">(i)</span> Individual diagnosed with cancer if the individual is an adult; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(1)(e)(ii)">(ii)</span> Parent or guardian if the individual diagnosed with cancer is younger than 18 years old;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(2)">(2)</span> A letter written by the individual’s physician on the physician’s letterhead:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(2)(a)">(a)</span> Confirming:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(2)(a)(i)">(i)</span> That the individual has been diagnosed with or treated for cancer or the individual has a finding suggestive of cancer and needs to obtain a cancer diagnosis; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(2)(a)(ii)">(ii)</span> The dates of diagnosis or treatment; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(2)(b)">(b)</span> Containing the physician's:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(2)(b)(i)">(i)</span> Full name;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(2)(b)(ii)">(ii)</span> Address;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(2)(b)(iii)">(iii)</span> Specialty; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(2)(b)(iv)">(iv)</span> Medical license number;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(3)">(3)</span> Proof of current Maryland residency for at least 6 months before the application date for each individual for whom grant funds are being requested in one of the following forms:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(3)(a)">(a)</span> Maryland driver’s license or State identification card;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(3)(b)">(b)</span> Lease or rental agreement;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(3)(c)">(c)</span> Property tax bill;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(3)(d)">(d)</span> Motor vehicle registration;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(3)(e)">(e)</span> Pay check or stub with name and home address;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(3)(f)">(f)</span> Utility bill;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(3)(g)">(g)</span> Voter registration card; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(3)(h)">(h)</span> W-2 statement issued not more than 12 months ago;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(4)">(4)</span> Proof of annual family income for each individual for whom grant funds are being requested, including a copy of at least one of the following:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(4)(a)">(a)</span> Most recent:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(4)(a)(i)">(i)</span> Income tax return; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(4)(a)(ii)">(ii)</span> W-2 form;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(4)(b)">(b)</span> Pay stubs for two:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(4)(b)(i)">(i)</span> Consecutive pays; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(4)(b)(ii)">(ii)</span> Pays in the same month;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(4)(c)">(c)</span> Social security entitlement letter; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(4)(d)">(d)</span> Notarized letter from the individual stating that the individual is not working and does not have any income;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(5)">(5)</span> Documentation of the eligibility of the individual for grant funds, including:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(5)(a)">(a)</span> The family size of the individual for whom the applicant is applying; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(5)(b)">(b)</span> The family’s annual household income;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(6)">(6)</span> Certification that the applicant will:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(6)(a)">(a)</span> Keep financial records, as described in <a class="internal-link " href="/us/md/exec/comar/10.14.05.16#B" title="">Regulation .16B of this chapter</a>;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(6)(b)">(b)</span> Send demographic and fiscal information on each individual covered to the CCPC at the end of the grant period; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(6)(c)">(c)</span> Act as the authorized representative of the individual.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(7)">(7)</span> Attestation that grant funds will not be used to supplant any existing funding for this cancer treatment activity; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(8)">(8)</span> If the applicant currently receives funding for a similar cancer treatment activity, a list of the funding:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(8)(a)">(a)</span> Source;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(8)(b)">(b)</span> Amount; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#C(8)(c)">(c)</span> Period for the activity.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#D">D.</span> An applicant seeking a cancer treatment grant to pay for deductibles and patient contribution costs through their health insurance policy under <a class="internal-link " href="/us/md/exec/comar/10.14.05.08#E(2)" title="">Regulation .08E(2) of this chapter</a> shall include in the Department’s application packet:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#D(1)">(1)</span> A completed and signed Maryland Cancer Fund — Cancer Treatment Grant application that;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#D(1)(a)">(a)</span> Certifies that the applicant shall pay:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#D(1)(a)(i)">(i)</span> The deductible and patient contribution amount; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#D(1)(a)(ii)">(ii)</span> Costs for services not covered under the individual’s health insurance policy for a time period not to exceed 1 year; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#D(1)(b)">(b)</span> Includes a treatment plan for a total request not to exceed a specified amount, as determined by the Department, per individual per year, including the:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#D(1)(b)(i)">(i)</span> Deductible and patient contribution amount; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#D(1)(b)(ii)">(ii)</span> Costs for services not covered under the individual’s health insurance policy.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#D(2)">(2)</span> Documentation of the individual’s health insurance policy.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#E">E.</span> An applicant seeking a cancer treatment grant to pay directly for cancer treatment costs under <a class="internal-link " href="/us/md/exec/comar/10.14.05.08#E(3)" title="">Regulation .08E(3) of this chapter</a> shall include in the Department’s application packet:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#E(1)">(1)</span> A completed Maryland Cancer Fund — Cancer Treatment Grant application; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#E(2)">(2)</span> A signed document that certifies that the applicant shall pay directly for cancer treatment costs for the individual for a time period not to exceed 1 year; and certifies that the applicant shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#E(2)(a)">(a)</span> Reimburse the provider in an amount not greater than the Medical Assistance rate for the medical procedure or the HSCRC-regulated rate for the medical procedure performed, if the medical procedure is performed in a HSCRC-regulated facility; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#E(2)(b)">(b)</span> Accept the Medical Assistance rate as payment in full for the cancer treatment procedures performed, if the applicant is a medical provider; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#E(3)">(3)</span> Includes a treatment plan for a total request not to exceed $20,000 per individual, including:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#E(3)(a)">(a)</span> The planned cancer treatment procedures; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.14#E(3)(b)">(b)</span> The Medical Assistance or HSCRC-regulated rate for each procedure.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.14.05.15" data-order="|10|14|05|.15|" data-ref-path="10|14|05|.15" class="h__section">.15 Grant Application Review and Approval and Grant Extensions.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#A">A.</span> Each fiscal year the CCPC shall determine:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#A(1)">(1)</span> The amount of money available for grants under the Maryland Cancer Fund;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#A(2)">(2)</span> The allocation of funding for cancer:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#A(2)(i)">(i)</span> Research;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#A(2)(ii)">(ii)</span> Primary prevention;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#A(2)(iii)">(iii)</span> Secondary prevention; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#A(2)(iv)">(iv)</span> Treatment; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#A(3)">(3)</span> The maximum grant award amount for each type of grant.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#B">B.</span> Each year the Department shall consider for award, funding for one or more of the following types of grant applications for cancer:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#B(1)">(1)</span> Research;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#B(2)">(2)</span> Primary prevention;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#B(3)">(3)</span> Secondary prevention; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#B(4)">(4)</span> Treatment.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#C">C.</span> The CCPC shall develop one or more evaluation committees or shall contract with one or more external consultants with expertise in cancer research and prevention to review the cancer research and primary prevention and secondary prevention grant applications that are submitted for funding under the Maryland Cancer Fund.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#D">D.</span> Due to the need for timeliness in the cancer treatment grants, the CCPC shall review each application for cancer treatment.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#E">E.</span> The evaluation committee or external consultants shall review:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#E(1)">(1)</span> Cancer research grant applications based on:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#E(1)(a)">(a)</span> Scientific need;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#E(1)(b)">(b)</span> The degree to which the cancer research plan will achieve the goals and objectives set forth in the plan;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#E(1)(c)">(c)</span> The inclusion of a plan for Institutional Review Board approval;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#E(1)(d)">(d)</span> The feasibility of the timeline in delivering goals and objectives of the plan;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#E(1)(e)">(e)</span> The experience and expertise of the principal investigator;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#E(1)(f)">(f)</span> The degree to which a grant application addresses eliminating disparities between racial and ethnic minorities and the white population;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#E(1)(g)">(g)</span> Whether the research is recommended in the Maryland Comprehensive Cancer Plan;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#E(1)(h)">(h)</span> The lack of other resources or funding for the proposed research; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#E(1)(i)">(i)</span> The amount of the funding requested;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#E(2)">(2)</span> Cancer primary prevention grant applications based on:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#E(2)(a)">(a)</span> The need for the cancer primary prevention activity;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#E(2)(b)">(b)</span> The previously documented effectiveness of the primary prevention intervention;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#E(2)(c)">(c)</span> The degree to which the cancer primary prevention plan will achieve the goals and objectives set forth in the plan;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#E(2)(d)">(d)</span> The degree to which a grant application addresses eliminating disparities between racial and ethnic minorities and the white population;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#E(2)(e)">(e)</span> The experience of the applicant in cancer primary prevention;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#E(2)(f)">(f)</span> Whether the primary prevention intervention is recommended in the Maryland Comprehensive Cancer Control Plan;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#E(2)(g)">(g)</span> The lack of other resources or funding for the proposal; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#E(2)(h)">(h)</span> The amount of funding requested; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#E(3)">(3)</span> Cancer secondary prevention grant applications based on:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#E(3)(a)">(a)</span> The previously documented effectiveness of the secondary prevention intervention;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#E(3)(b)">(b)</span> The need for the cancer secondary prevention intervention in the population group to be served;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#E(3)(c)">(c)</span> The degree to which the cancer secondary prevention plan will achieve the goals and objectives of the plan;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#E(3)(d)">(d)</span> The feasibility of the timeline in delivering the goals and objectives of the plan;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#E(3)(e)">(e)</span> The extent to which medical guidelines for screening and diagnosis are being followed;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#E(3)(f)">(f)</span> The percent of the budget allocated to clinical services;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#E(3)(g)">(g)</span> The degree to which the grant application addresses eliminating disparities between racial and ethnic minorities and the white population;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#E(3)(h)">(h)</span> The experience of the applicant in cancer secondary prevention;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#E(3)(i)">(i)</span> Whether the secondary prevention intervention is recommended in the Maryland Comprehensive Cancer Control Plan;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#E(3)(j)">(j)</span> The lack of other resources or funding for the proposal; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#E(3)(k)">(k)</span> The amount requested.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#F">F.</span> After reviewing each cancer research, primary prevention, and secondary prevention grant application, the evaluation committee or external consultant shall make a recommendation to the CCPC about whether to award grant funds to each applicant.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#G">G.</span> The CCPC shall review each cancer treatment application based on:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#G(1)">(1)</span> Completeness;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#G(2)">(2)</span> Availability of funds; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#G(3)">(3)</span> Whether the application meets the relevant application process requirements set forth in this chapter.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#H">H.</span> The Director of the CCPC shall recommend an application to the Secretary for approval based upon:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#H(1)">(1)</span> The evaluation committee's or external consultant's recommendations for awarding the cancer research, primary prevention, secondary prevention, and treatment grants for each application; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#H(2)">(2)</span> The availability of funds.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#I">I.</span> The Secretary shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#I(1)">(1)</span> Consider the grant recommendations of the CCPC for the cancer:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#I(1)(a)">(a)</span> Research;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#I(1)(b)">(b)</span> Primary prevention;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#I(1)(c)">(c)</span> Secondary prevention; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#I(1)(d)">(d)</span> Treatment; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#I(2)">(2)</span> Make the final determination on which grant applications to approve.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#J">J.</span> A grant period expires 1 year from the date of award of the grant, unless extended as set forth in <a class="internal-link " href="/us/md/exec/comar/10.14.05.16" title=".16 Payments, Terms and Conditions of Grant Awards, and Terminations.">Regulation .16 of this chapter</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#K">K.</span> A person awarded a grant under this chapter may apply for a no-cost extension of the grant period for the award before the expiration of the grant period, as set forth in <a class="internal-link " href="/us/md/exec/comar/10.14.05.15#J" title="">§J of this regulation</a>, by submitting a written request for an extension to the CCPC.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#L">L.</span> In evaluating whether to grant an extension of the grant period, the CCPC:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#L(1)">(1)</span> Shall assess whether progress has been made on the grant; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#L(2)">(2)</span> If progress has been made based on the reports submitted pursuant to <a class="internal-link " href="/us/md/exec/comar/10.14.05.16#C" title="">Regulation .16C of this chapter</a>, may recommend to the Secretary that an extension be granted.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#M">M.</span> The Secretary may approve an extension for up to 1 year based on:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#M(1)">(1)</span> The recommendation of the CCPC; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.15#M(2)">(2)</span> Whether progress has been shown on the grant pursuant to <a class="internal-link " href="/us/md/exec/comar/10.14.05.16#C" title="">Regulation .16C of this chapter</a>.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.14.05.16" data-order="|10|14|05|.16|" data-ref-path="10|14|05|.16" class="h__section">.16 Payments, Terms and Conditions of Grant Awards, and Terminations.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#A">A.</span> Payments Under the Grant.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#A(1)">(1)</span> The Department may not make more than monthly payments during the grant period to a person awarded a grant under this chapter.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#A(2)">(2)</span> Before the first payment under the grant, at the request of the person awarded the grant under this chapter, the Department may approve an advanced payment for the grant based on financial need, if a request for advanced payment was specified in the grant application.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#A(3)">(3)</span> If a financial or progress report required in §B or C of this regulation is overdue, the Department may withhold payment until the report is submitted.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#B">B.</span> Financial Reports and Records.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#B(1)">(1)</span> A person awarded a grant shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#B(1)(a)">(a)</span> Establish a separate account to track expenditures under the grant;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#B(1)(b)">(b)</span> Maintain accurate records, including documentation of each transaction pertaining to the grant; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#B(1)(c)">(c)</span> Submit to the Department monthly invoices for payment and an annual financial expenditure report containing the signature of the financial officer of the entity affiliated with the grant award.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#B(2)">(2)</span> The Department may audit the accounts referenced in <a class="internal-link " href="/us/md/exec/comar/10.14.05.16#B(1)" title="">§B(1) of this regulation</a> at any time.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#B(3)">(3)</span> A person awarded a grant under this chapter shall submit to the Department within 90 days after the date the grant period ends:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#B(3)(a)">(a)</span> A final financial expenditure report; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#B(3)(b)">(b)</span> A refund of any unexpended funds.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#B(4)">(4)</span> A person awarded a grant under this chapter shall retain all records pertaining to a grant award for 3 years from the date the final financial expenditure report is submitted under <a class="internal-link " href="/us/md/exec/comar/10.14.05.16#B(3)" title="">§B(3) of this regulation</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#B(5)">(5)</span> In the case of an audit or litigation, the Department may extend the time period under §B(3) or (4) of this regulation until the completion of the audit or litigation.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#C">C.</span> Progress Reports.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#C(1)">(1)</span> A grantee shall submit to the CCPC three copies of:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#C(1)(a)">(a)</span> An interim report describing the progress of the grant:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#C(1)(a)(i)">(i)</span> 6 months after the date of award of the grant; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#C(1)(a)(ii)">(ii)</span> Every 6 months until the end of the grant; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#C(1)(b)">(b)</span> A comprehensive final report, not later than 60 days after the date the grant period ends, that provides a summary of all of the activity conducted under the grant.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#C(2)">(2)</span> A grantee receiving a cancer research grant shall include the following information in the comprehensive final report:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#C(2)(a)">(a)</span> Hypothesis;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#C(2)(b)">(b)</span> Methods;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#C(2)(c)">(c)</span> Results;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#C(2)(d)">(d)</span> Discussion of results and limitations of the research; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#C(2)(e)">(e)</span> Conclusion.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#C(3)">(3)</span> A grantee receiving a cancer primary prevention or secondary prevention grant shall include the following information in the comprehensive final report:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#C(3)(a)">(a)</span> Number of individuals served, by:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#C(3)(a)(i)">(i)</span> Type of service;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#C(3)(a)(ii)">(ii)</span> Age;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#C(3)(a)(iii)">(iii)</span> Race; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#C(3)(a)(iv)">(iv)</span> Gender;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#C(3)(b)">(b)</span> Number of individuals with abnormal screening results, by type of cancer;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#C(3)(c)">(c)</span> Number of cancers diagnosed; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#C(3)(d)">(d)</span> Other outcome measures.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#C(4)">(4)</span> A grantee receiving a cancer treatment grant shall include the following information in the comprehensive final report for each individual receiving funds for cancer treatment:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#C(4)(a)">(a)</span> Type of cancer;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#C(4)(b)">(b)</span> Stage of cancer at diagnosis;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#C(4)(c)">(c)</span> Age;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#C(4)(d)">(d)</span> Race;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#C(4)(e)">(e)</span> Gender;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#C(4)(f)">(f)</span> County; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#C(4)(g)">(g)</span> Amount of funds expended.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#C(5)">(5)</span> The Department shall keep research results confidential as required by Health-General Article, §§4-101 — 4-103, Annotated Code of Maryland.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#D">D.</span> Publications.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#D(1)">(1)</span> A person who publishes results from activities supported by a grant approved by the Secretary under this chapter shall include in the publication the following acknowledgement: "Supported in part with funds from the Maryland Cancer Fund of the Maryland Department of Health."</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#D(2)">(2)</span> A person awarded a grant under this chapter shall provide the Department with three copies of any published article pertaining to the activities conducted under the grant.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#E">E.</span> Ownership of Equipment. A person awarded a grant under this chapter:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#E(1)">(1)</span> Shall ensure that equipment purchased under a grant under this chapter is used for the sole purpose of the grant;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#E(2)">(2)</span> Shall keep an inventory of all equipment purchased; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#E(3)">(3)</span> May not transfer the equipment to another entity without the written permission of the Department.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#F">F.</span> Termination.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#F(1)">(1)</span> The Secretary may terminate a grant:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#F(1)(a)">(a)</span> If a grantee fails to comply with:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#F(1)(a)(i)">(i)</span> The requirements of this chapter; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#F(1)(a)(ii)">(ii)</span> State, federal, and municipal laws applicable to the performance of research under the grant;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#F(1)(b)">(b)</span> If a grantee fails to carry out the purposes for which the grant was awarded;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#F(1)(c)">(c)</span> In compliance with a court order; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#F(1)(d)">(d)</span> At the request of the grantee.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#F(2)">(2)</span> The Department and the State are not responsible for any expenses incurred by a grantee after cancellation of a grant.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#F(3)">(3)</span> The grantee shall return all unexpended funds to the Department within 60 days of termination of a grant.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#G">G.</span> Compliance with Existing Laws. A person awarded a grant under this chapter shall ensure that an activity conducted in the performance of the grant is in compliance with all State, federal, and local laws.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#H">H.</span> Liability.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#H(1)">(1)</span> A person awarded a grant under this chapter is solely responsible for the person's actions pertaining to research conducted under a grant award.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#H(2)">(2)</span> The State and the Department are not liable for any claims, losses, liabilities, expenses, or damages arising from research conducted under a grant awarded under this chapter.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.14.05.16#I">I.</span> Grant Agreements. A person awarded a grant under this chapter shall enter into a grant agreement with the Department.</p>
                <hr class="section-separator" aria-hidden="true"/>
              </div>
            </article>
          </main>
          <nav id="area__navigation_mini" class="ns__document__maryland-dsd" aria-label="Previous and next article links">
            <section>
              <a href="/us/md/exec/comar/10.14.04" aria-label="Chapter 04 Breast Cancer Program">
                <div class="h__ui">Previous</div>
                <span>Chapter 04 Breast Cancer Program</span>
              </a>
            </section>
            <section>
              <a href="/us/md/exec/comar/10.14.06" aria-label="Chapter 06 Cigarette Restitution Fund Program">
                <div class="h__ui">Next</div>
                <span>Chapter 06 Cigarette Restitution Fund Program</span>
              </a>
            </section>
          </nav>
        </div>
      </div>
      <footer id="section__footer" class="ns__document__maryland-dsd">
        <div id="section__footer__inner" class="ns__document__maryland-dsd">
          <div id="area__footer__content" class="ns__document__maryland-dsd">
<p>This version of the laws and codes on this website is licensed under the <a href="https://creativecommons.org/licenses/by-nc-sa/4.0/">CC BY-NC-SA 4.0</a> license with copyright held by the State of Maryland.</p><p>This version of the laws and codes on this website will be dedicated to the public domain under the <a href="https://creativecommons.org/publicdomain/zero/1.0/">CC0 1.0</a> license 180 days after publication.</p>
<p>
      Please do not scrape. Instead, bulk download the CC BY-NC-SA-4.0 <a href="https://github.com/maryland-dsd/law-html">HTML</a> or <a href="https://github.com/maryland-dsd/law-xml">XML</a> or CC0 <a href="https://github.com/maryland-dsd/law-html-cc0">HTML</a> or <a href="https://github.com/maryland-dsd/law-xml-cc0">XML</a>.
    </p><p>Powered by the non-profit <a href="https://www.openlawlib.org/">Open Law Library</a>.</p></div>
        </div>
      </footer>
    </div>
    <!--Piwik analytics-->
    <noscript>
      <img src="/_analytics/pixel.png" style="border:0;" alt=""/>
    </noscript>
  </body>
</html>
